FEXOFENADINE AS A PROBE FOR ENTEROCYTE P GLYCOPROTEIN

非索非那定作为肠细胞 P 糖蛋白的探针

• 批准号: 6297204
• 负责人: KENNETH S LOWN
• 金额: $ 0.02万
• 依托单位: UNIVERSITY OF MICHIGAN AT ANN ARBOR
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6297204
• 关键词: P glycoprotein; antihistamines; bioassay; biomarker; clinical research; clinical trials; gastrointestinal drug absorption; gene expression; human subject; oral administration; pharmacokinetics; protein structure function

Interpatient variation in expression of P-glycoprotein in the intestine has been shown to substantially contribute to the variability in the oral availability of cyclosporin A (1). A probe based test capable of quantitating P-glycoprotein would be very valuable in characterizing the genetic and non genetic factors that underlie interindividual variation in intestinal expression of P-glycoprotein and to further extablish the role of P-glycoprotein in the oral kinetics of other drugs. This study will directly test the hypothesis that orally administered fexofenadine (Allgra) can be used as an assay for P-glycoprotein function.

研究表明，患者间肠道P-糖蛋白表达的差异在很大程度上导致了环孢素A口服利用度的差异（1）。 一种基于探针的能够定量P-糖蛋白的检测方法在表征P-糖蛋白肠道表达个体间差异的遗传和非遗传因素以及进一步确定P-糖蛋白在其他药物口服动力学中的作用方面将是非常有价值的。 本研究将直接检验口服非索非那定（Allgra）可用作P-糖蛋白功能测定的假设。